Introduction Emerging adulthood (between the ages 18–25 years) has been conceptualized
as a specific developmental stage based on unique psychosocial characteristics. Opioids …

Abstract Emerging adults (18–25 years old) are often poorly retained in substance use
disorder treatment. Office-based buprenorphine often enhances treatment retention among …

Background Buprenorphine has become the major treatment for opioid use disorder (OUD)
but data on long treatment term retention and its correlates are sparse. Methods All veterans …

Abstract Background and Aims Partial opioid agonist medications for opioid use disorder
reduce mortality and morbidity, however long-term retention in treatment is challenging. The …

Purpose To describe attrition patterns of opioid use disorder (OUD) patients treated with
buprenorphine (BUP) and to assess how clinical, sociodemographic, or BUP medication …

Background and Objectives Despite the dramatic increase in the use of buprenorphine for
the treatment of opioid dependence, clinical outcomes of this treatment approach continue to …

Introduction Buprenorphine, a medication for opioid use disorder (OUD), can be
administered within primary care; however, little is known about characteristics associated …

Introduction Controversy exists regarding effective sublingual buprenorphine dosing for
treatment of opioid use disorder (OUD), leading to dose caps of 16 mg per day. The Project …

Background and Objectives Despite high comorbidity between substance use disorders and
other mental health diagnoses, there is a paucity of literature on buprenorphine treatment …

Background and Objectives Identifying predictors of early drop out from outpatient treatment
of opioid use disorder (OUD) with buprenorphine/naloxone (BN) may improve care for …